Mesa Laboratories (MLAB) investor relations material

Business Overview and Strategy

• Focuses on mission-critical quality controls for regulated markets, supporting drug development, bioproduction, and healthcare delivery, with an emphasis on protecting vulnerable populations.

• Operates in four segments: sterility controls, biopharmaceutical development, genomics, and calibration solutions, with diversified, high-growth verticals and little exposure to NIH funding.

• Maintains a disciplined management team and applies a lean-based operating model called the Mesa Way, prioritizing continuous improvement, customer-centric value streams, and operational excellence.

• Expands through accretive, strategic M&A, leveraging complementary products and geographic reach, while pursuing organic growth by penetrating new applications and expanding in APAC.

• Maintains a recurring revenue model, with over 75% from consumables and services, and strong regulatory drivers reducing volatility.

Financial Performance and Growth

• FY25 revenues reached $241M, with a five-year CAGR of 15.4% and core organic revenue growth of 5%.

• Gross profit margin for FY25 was 62.6%, with AOI excluding unusual items at 23.5% of revenue.

• Long-term financial performance shows a 2015-25 CAGR of 13% for revenues and 9% for AOI.

• Recent acquisitions, such as GKE, have been accretive, with projected revenues of $21M–$22M and AOI margins of 37–40%.

• Debt reduced from 3.8x to below 3x in two years, with a target of under 2.5x in the next 12 months, and $21.3M in cash.

Market Dynamics and Headwinds

• Navigated industry headwinds including bioprocess destocking, academic funding shifts, CapEx cycles, and regulatory changes in China.

• Most headwinds, except for China, have largely passed, with expectations for a natural lift as conditions normalize.

• Smaller companies have faced valuation compression, but performance has outpaced larger diversified peers.

• Clinical Genomics faces headwinds in China but expects growth from PGx testing as reimbursement mandates increase.

• Anticipates market optimism and increased clinical trial starts to drive future growth.